Featured content
Making historical toxicology data work harder in safety assessment
Historical toxicology data is often underused. Find out how Virtual Control Groups and AI could help researchers strengthen safety assessment while making better use of existing data.
ArticleHow AI and human biology data led to a new addiction drug candidate
How can human biology data improve target selection? Learn how one discovery programme identified a potential new treatment for opioid use disorder.
ArticleAs AI agents mature, the question becomes: what is the human for?
In part II of his conversation with Dr Nick Lynch, founder of Curlew Research, Raminderpal Singh asks the uncomfortable questions that we may not yet be equipped to answer – or ready to face.
ArticleSynthetic iMSCs: reprogramming ovarian cancer from the inside out
Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic iMSCs could reprogramme the tumour microenvironment and restore anti-tumour immunity.
News
NewsEuropean initiative aims to bring molecular dynamics into mainstream drug discovery
What if the vast amounts of data generated by molecular dynamics simulations could be routinely shared and reused? A new €10 million European initiative aims to do just that, helping researchers gain a deeper understanding of protein behaviour and drug-target interactions.
NewsOral antiviral GHP-88310 candidate shown to block measles transmission in ferret model
An experimental oral antiviral has demonstrated the ability to prevent both airborne and contact-based transmission of a measles surrogate virus in ferrets, offering a potential new tool to complement vaccination during outbreaks.
News3D genome reorganisation identified as Alzheimer’s disease molecular hallmark
An international study combining single-cell genomics, spatial transcriptomics and artificial intelligence has identified large-scale changes in three-dimensional genome organisation in Alzheimer’s-affected brain cells, establishing chromatin architecture as a previously overlooked component of the disease’s molecular pathology and a potential framework for future therapeutic targeting.
NewsInsilico Medicine nominates ISM9528 non-opioid chronic pain candidate using AI
Insilico Medicine has nominated ISM9528, an orally available, brain-penetrant non-opioid candidate targeting a previously unrecognised pain mechanism, as its 31st AI-generated preclinical compound since 2021, with efficacy exceeding morphine in some preclinical models.
From our partners
Article
Antibody recycling, FcRn and the next generation of biologics
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
Article
Flow-based human tumour models reveal immune responses missed by static culture
Static cultures can miss critical immune–tumour interactions. Learn how the Mera™ flow-based human tissue model better captures T-cell activity to strengthen preclinical immunotherapy research.
Opinion and interviews
The global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
Meeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
Webinar
Building better therapeutic antibodies: the science, progress and problems to solve
As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
Meeting ethical & regulatory requirements when using human biological specimens
Building better therapeutic antibodies: the science, progress and problems to solve
On-demand Webinars
- Previous
- Next
